

**Fermenta Biotech Limited** (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



F.No.:49

February 11, 2021

Corporate Relations  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

Dear Sir,

**Sub: Outcome of Board Meeting and Unaudited Financial Results - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Ref: Scrip Code 506414**

We write to inform you that the Board of Directors of the Company at its meeting held on February 11, 2021 has, *inter alia*:

- (a) approved the unaudited financial results for the quarter and nine months ended December 31, 2020 (Standalone and Consolidated) as enclosed.

We are enclosing herewith Limited Review Report dated February 11, 2021 (along with the aforesaid Consolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, Deloitte Haskins & Sells LLP; and

- (b) approved and authorized to make an application to National Stock Exchange of India Limited ('NSE') seeking listing and trading of equity shares of the Company on the stock exchange platform of NSE through a direct listing route.

Kindly take the above on record.

The Board meeting commenced at 12 noon and concluded at 1:45 p.m.

Thanking you,  
Yours faithfully,

**For Fermenta Biotech Limited (Formerly known as DIL Limited)**

**Srikant Sharma**

Company Secretary & Vice President (Legal)

Membership No. FCS3617

Encl: As above

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
Fermenta Biotech Limited (Formerly known as DIL Limited)**

1. We have reviewed the Standalone Unaudited Financial Results and also the Consolidated Unaudited Financial Results of **Fermenta Biotech Limited** (Formerly known as DIL Limited) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the profit/(loss) after tax and total comprehensive income/loss of its associate for the quarter and nine months ended December 31, 2020, included in the accompanying Statement of Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2020 ("the Statement"), being submitted by the Parent, pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Management of the Parent and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

ANS

RKH

# Deloitte Haskins & Sells LLP

4. The Consolidated unaudited financial results in the Statement includes the interim financial results / interim financial information of the following entities:

## **Parent**

1. Fermenta Biotech Limited (Formerly known as DIL Limited)

## **Subsidiaries**

2. Aegean Properties Limited
3. CC Square Films Limited
4. G. I. Biotech Private Limited
5. Fermenta Biotech (UK) Limited
6. Fermenta Biotech GmbH
7. Fermenta Biotech USA, LLC
8. Fermenta USA LLC

## **Associate**

9. Health and Wellness India Private Limited

5. The Parent has given (unsecured) Inter-corporate deposits aggregating ₹ 1,245.00 Lakhs in various tranches to another entity during the calendar year 2019. The amount outstanding as on December 31, 2020 is ₹ 1,407.36 Lakhs, including interest of ₹ 162.36 Lakhs. However as per the terms of the ICD agreement the deposits are repayable within one year from the date of entering into the agreement and are further renewable such that the total period of deposits does not exceed three years. No Interest has been recovered on these deposits. As per that entity's latest available audited financial statements for the year ended March 31, 2019, the entity is predominantly dependent on borrowings, including from banks, and the net worth is marginal. For the reasons stated in Note 7 to the Statement, the Management of the Parent believes that no impairment on these Inter-corporate deposits including interest accrued on such deposits is deemed necessary. The other entity referred above has repaid an amount of ₹ 92.71 Lakhs subsequent to the nine months ended December 31, 2020 towards the aggregate outstanding of ₹ 1,407.36 Lakhs (i.e. ICD and interest thereon as disclosed above). Having regard to the foregoing and in the absence of sufficient appropriate information, we are unable to comment whether the aforesaid Inter-corporate deposits including interest accrued on such deposits would be recoverable including the consequential impact, if any, of such impairment that may be required to be made in both, in the standalone unaudited financial results and in the consolidated unaudited financial results.

This matter was also qualified in our audit report on the audited standalone and consolidated financial results for the quarter and year ended March 31, 2020 and in our review report on the unaudited standalone and consolidated financial results for the subsequent periods.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, except for the possible effects of the matter described in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

AMS

RKB

# Deloitte Haskins & Sells LLP

7. We did not review the interim financial information of 3 subsidiaries included in the consolidated unaudited financial results, included in the Statement, whose interim financial information reflect total revenue of ₹ 4.50 Lakhs and ₹ 13.50 Lakhs for the quarter and nine months ended December 31, 2020, respectively, and total net profit after tax of ₹ 2.28 Lakhs and ₹ 7.05 Lakhs and total comprehensive income (net) of ₹ 2.28 Lakhs and ₹ 7.05 Lakhs for the quarter and nine months ended December 31, 2020, respectively, as considered in the consolidated unaudited financial results, included in the Statement. The above figures are before giving effect of any consolidation adjustments. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management of the Parent and our conclusion on the consolidated unaudited financial results, included in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the consolidated unaudited financial results, included in the Statement, is not modified in respect of these matters.

8. The consolidated unaudited financial results, included in the Statement, include the interim financial information of 4 subsidiaries which has not been reviewed by their auditors, whose interim financial information reflect total revenue of ₹ 498.42 Lakhs and ₹ 707.65 Lakhs for the quarter and nine months ended December 31, 2020, respectively, total net loss after tax of ₹ 98.23 Lakhs and ₹ 176.63 Lakhs and total comprehensive loss (net) of ₹ 98.23 Lakhs and ₹ 176.63 Lakhs for the quarter and nine months ended December 31, 2020, respectively, as considered in the consolidated unaudited financial results, included in the Statement. The above figures are before giving effect of any consolidation adjustments. The consolidated unaudited financial results also includes the Group's share of profit/ (loss) after tax of ₹ Nil and total comprehensive income/loss of ₹ Nil, both, for the quarter and nine months ended December 31, 2020, respectively, as considered in the consolidated unaudited financial results, included in the Statement, in respect of an associate, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management of the Parent, these interim financial information are not material to the Group.

Our Conclusion on the consolidated unaudited financial results, included in the Statement is not modified in respect of our reliance on the interim financial information certified by the Management of the Parent.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No. 36920)  
UDIN: 21036920AAAAAN475

Place: Mumbai  
Date: February 11, 2021

AMS *RKB*



Fermenta Biotech Limited (Formerly Known as DIL Limited)  
 CIN:L99999MH1951PLC008485  
 Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.  
 Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

| STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020 |   |               |               |              |                   |              |            |               |               |              |                   |              |            |
|--|---|---------------|---------------|--------------|-------------------|--------------|------------|---------------|---------------|--------------|-------------------|--------------|------------|
| Sr. No.  | Particulars   | Standalone    |               |              |                   |              |            | Consolidated  |               |              |                   |              |            |
|  |   | Quarter Ended |               |              | Nine Months Ended |              |            | Quarter Ended |               |              | Nine Months Ended |              |            |
|  |   | Unaudited     | Unaudited     | Unaudited    | Unaudited         | Unaudited    | Audited    | Unaudited     | Unaudited     | Unaudited    | Unaudited         | Unaudited    | Audited    |
|  |   | December 31,  | September 30, | December 31, | December 31,      | December 31, | March 31,  | December 31,  | September 30, | December 31, | December 31,      | December 31, | March 31,  |
|  | 2020  | 2020          | 2019          | 2020         | 2019              | 2020         | 2020       | 2020          | 2019          | 2020         | 2019              | 2020         |            |
| 1  | Income  |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | a) Revenue from operations  | 8,766.96      | 9,331.94      | 6,645.21     | 28,191.82         | 22,841.08    | 30,050.65  | 8,998.53      | 9,337.35      | 6,645.14     | 27,780.36         | 22,840.86    | 29,294.92  |
|  | b) Other income   | 66.08         | 93.72         | 344.33       | 287.46            | 966.78       | 1,231.32   | 68.97         | 165.17        | 348.05       | 361.67            | 968.48       | 1,232.30   |
| 2  | Total Income (a+b)  | 8,833.04      | 9,425.66      | 6,989.54     | 28,479.28         | 23,807.86    | 31,281.97  | 9,067.50      | 9,502.52      | 6,993.19     | 28,142.03         | 23,809.34    | 30,527.22  |
| 3  | Expenses  |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | a) Cost of materials consumed   | 3,888.34      | 2,893.10      | 2,266.92     | 10,125.78         | 7,363.62     | 10,296.33  | 3,903.40      | 3,017.41      | 2,266.92     | 10,431.55         | 7,363.62     | 10,561.26  |
|  | b) Purchases of stock-in-trade  | 1.70          | 21.89         | 20.28        | 25.59             | 36.92        | 50.15      | 197.84        | 21.89         | 20.28        | 221.73            | 36.92        | 50.15      |
|  | c) Change in inventories of finished goods, stock-in-trade and work-in-progress                                       | (1,214.05)    | (160.07)      | (588.93)     | (958.44)          | (1,634.57)   | (2,078.85) | (1,227.59)    | (281.39)      | (588.93)     | (1,786.21)        | (1,634.57)   | (2,708.90) |
|  | d) Employee benefits expense  | 1,492.05      | 1,439.39      | 1,247.37     | 4,392.84          | 3,904.66     | 5,003.15   | 1,504.18      | 1,439.39      | 1,247.37     | 4,404.97          | 3,904.66     | 5,003.15   |
|  | e) Finance costs  | 396.26        | 547.18        | 539.31       | 1,305.55          | 1,528.43     | 1,932.04   | 392.76        | 544.67        | 534.81       | 1,295.05          | 1,514.92     | 1,914.04   |
|  | f) Depreciation and amortisation expense  | 467.25        | 454.12        | 379.84       | 1,308.91          | 1,101.16     | 1,493.83   | 499.69        | 478.48        | 380.69       | 1,390.28          | 1,103.72     | 1,499.97   |
|  | g) Commission on sales  | 50.75         | 196.98        | (94.79)      | 689.69            | 978.48       | 908.81     | 53.77         | 196.98        | (94.79)      | 692.71            | 878.48       | 908.81     |
|  | h) Other expenses   | 2,232.86      | 2,175.96      | 2,400.13     | 6,350.65          | 6,694.67     | 8,921.85   | 2,346.97      | 2,250.52      | 2,415.88     | 6,666.93          | 6,711.21     | 8,956.73   |
|  | Total expenses (a to h)   | 7,315.16      | 7,568.54      | 6,170.13     | 23,240.57         | 19,873.37    | 26,527.31  | 7,671.02      | 7,667.95      | 6,182.23     | 23,317.01         | 19,878.96    | 26,185.21  |
| 4  | Profit before tax (2-3)   | 1,517.88      | 1,857.12      | 819.41       | 5,238.71          | 3,934.49     | 4,754.66   | 1,396.48      | 1,834.57      | 810.96       | 4,825.02          | 3,930.38     | 4,342.01   |
| 5  | Tax expense (see Note 4)  |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | a) Current tax  | 267.85        | 329.50        | 146.69       | 937.35            | 186.52       | 336.55     | 268.64        | 330.29        | 330.29       | 71.06             | (1,898.26)   | (1,948.89) |
|  | b) Deferred tax charge/(credit)   | 144.94        | 33.18         | (302.47)     | 71.08             | (1,898.28)   | (1,948.89) | 144.93        | 33.17         | (302.51)     | 1,010.77          | (1,709.03)   | (1,610.01) |
|  | Total tax expense (a+b)   | 412.79        | 362.68        | (155.78)     | 1,008.43          | (1,711.76)   | (1,612.37) | 413.57        | 363.46        | (154.94)     | 1,010.77          | (1,709.03)   | (1,610.01) |
| 6  | Profit for the period after tax but before share of profit/(loss) of an associate and non-controlling interests (4-5) | 1,105.09      | 1,494.45      | 975.20       | 4,230.28          | 5,646.26     | 6,367.04   | 982.91        | 1,471.11      | 965.90       | 3,814.25          | 5,639.41     | 5,952.02   |
| 7  | Share of profit / (loss) of an associate  | -             | -             | -            | -                 | -            | -          | -             | -             | -            | -                 | -            | -          |
| 8  | Net Profit after tax and share of profit/(loss) of an associate and but before non-controlling interests (6+7)        | 1,105.09      | 1,494.45      | 975.20       | 4,230.28          | 5,646.26     | 6,367.04   | 982.91        | 1,471.11      | 965.90       | 3,814.25          | 5,639.41     | 5,952.02   |
| 9  | Non-controlling interests   | -             | -             | -            | -                 | -            | -          | (3.16)        | (0.06)        | (0.66)       | (3.15)            | (0.45)       | 0.58       |
| 10   | Profit for the period after tax, share of profit/(loss) of an associate and non-controlling interests (8+9)           | 1,105.09      | 1,494.45      | 975.20       | 4,230.28          | 5,646.26     | 6,367.04   | 979.75        | 1,471.05      | 965.24       | 3,811.10          | 5,638.96     | 5,952.60   |
| 11   | Other Comprehensive Income  |               |               |              |                   |              |            |               |               |              |                   |              |            |
| (A)  | Items that will not be reclassified to Profit or Loss   | (1.03)        | 1.07          | 3.22         | 0.42              | 8.03         | 181.90     | (1.03)        | 1.07          | 3.22         | 0.42              | 8.03         | 181.90     |
| (B)  | Items that will be reclassified to Profit or Loss   | -             | -             | -            | -                 | -            | -          | (19.14)       | (4.27)        | -            | (28.66)           | -            | (8.33)     |
|  | Total other comprehensive Income/(Loss) (A+B)   | (1.03)        | 1.07          | 3.22         | 0.42              | 8.03         | 181.90     | (20.17)       | (3.20)        | 3.22         | (28.24)           | 8.03         | 173.57     |
| 12   | Total Comprehensive Income for the period/year (8+11)   | 1,104.06      | 1,495.52      | 978.42       | 4,230.70          | 5,654.29     | 6,548.94   | 962.74        | 1,467.91      | 969.12       | 3,786.01          | 5,647.44     | 6,125.59   |
|  | Attributable to:  |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | - Owners of the parent  |               |               |              |                   |              |            | 959.58        | 1,467.85      | 968.46       | 3,782.86          | 5,646.99     | 6,126.17   |
|  | - Non-controlling interests   |               |               |              |                   |              |            | 3.16          | 0.06          | 0.66         | 3.15              | 0.45         | (0.58)     |
| 13   | Paid-up equity share capital (Face value ₹ 5/- per share) - 2,88,47,322 number of equity shares (see Note 5)          | 1,442.37      | 1,442.37      | -            | 1,442.37          | -            | 1,442.37   | 1,442.37      | 1,442.37      | -            | 1,442.37          | -            | 1,442.37   |
|  | Paid-up equity share capital (Face value ₹ 5/- per share) - 96,15,774 number of equity shares                         | -             | -             | 480.79       | -                 | 480.79       | -          | -             | -             | 480.79       | -                 | 480.79       | -          |
| 14   | Earnings per equity share of ₹ 5 each [Post Bonus* (not annualised) - (see note 5)]                                   |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | *28,847,322 number of equity shares   |               |               |              |                   |              |            |               |               |              |                   |              |            |
|  | a) ₹ Basic  | 3.83          | 5.18          | 3.38         | 14.66             | 19.57        | 22.07      | 3.40          | 5.10          | 3.35         | 13.21             | 19.55        | 20.63      |
|  | b) ₹ Diluted  | 3.83          | 5.17          | 3.38         | 14.60             | 19.50        | 21.96      | 3.39          | 5.09          | 3.34         | 13.16             | 19.47        | 20.53      |

AMS  
 RKH

NOTES:

(₹. in Lakhs)

| Particulars                                     | Standalone           |                       |                      |                      |                      |                   |
|---|----------------------|-----------------------|----------------------|----------------------|----------------------|-------------------|
|   | Quarter ended        |                       |                      | Nine Months Ended    |                      | Year Ended        |
|   | Unaudited            | Unaudited             | Unaudited            | Unaudited            | Unaudited            | Audited           |
|   | December 31,<br>2020 | September 30,<br>2020 | December 31,<br>2019 | December 31,<br>2020 | December 31,<br>2019 | March 31,<br>2020 |
| Segment revenue                                 |                      |                       |                      |                      |                      |                   |
| - Bulk drugs/chemicals                          | 8,336.23             | 8,884.43              | 6,219.55             | 26,881.73            | 21,551.51            | 28,305.62         |
| - Property                                      | 430.72               | 447.52                | 425.66               | 1,310.09             | 1,501.90             | 1,945.05          |
| - Unallocated                                   | 66.09                | 93.71                 | 344.33               | 287.46               | 1,036.81             | 1,313.66          |
| Total   | 8,833.04             | 9,425.66              | 6,989.54             | 28,479.28            | 24,090.22            | 31,564.33         |
| Less : Inter-segment revenue                    | -                    | -                     | -                    | -                    | 282.36               | 282.36            |
| Total Income                                    | 8,833.04             | 9,425.66              | 6,989.54             | 28,479.28            | 23,807.86            | 31,281.97         |
| Segment results                                 |                      |                       |                      |                      |                      |                   |
| - Bulk drugs/chemicals                          | 1,752.11             | 2,220.25              | 765.14               | 6,044.84             | 4,840.87             | 5,958.00          |
| - Property                                      | 240.17               | 251.48                | 122.44               | 716.13               | 451.31               | 571.30            |
| - Unallocated (Net)                             | (78.14)              | (67.43)               | 471.14               | (216.71)             | 170.74               | 157.40            |
| Total   | 1,914.14             | 2,404.30              | 1,358.72             | 6,544.26             | 5,462.92             | 6,686.70          |
| Less: Inter-segment results                     | -                    | -                     | -                    | -                    | -                    | -                 |
| Total Profit before tax and before finance cost | 1,914.14             | 2,404.30              | 1,358.72             | 6,544.26             | 5,462.92             | 6,686.70          |
| Less : Finance costs                            | (396.26)             | (547.18)              | (539.31)             | (1,305.55)           | (1,528.43)           | (1,932.04)        |
| Total Profit before tax                         | 1,517.88             | 1,857.12              | 819.41               | 5,238.71             | 3,934.49             | 4,754.66          |
| Segment Assets                                  |                      |                       |                      |                      |                      |                   |
| - Bulk Drugs/chemicals                          | 48,260.05            | 44,807.48             | 38,897.65            | 48,260.05            | 38,897.65            | 40,418.44         |
| - Property                                      | 7,612.35             | 7,626.82              | 8,196.40             | 7,612.35             | 8,196.40             | 8,014.40          |
| - Unallocated                                   | 12,751.89            | 15,164.03             | 13,606.05            | 12,751.89            | 13,606.05            | 12,528.22         |
| Total Segment Assets                            | 68,624.29            | 67,598.33             | 60,700.10            | 68,624.29            | 60,700.10            | 60,961.06         |
| Segment Liabilities                             |                      |                       |                      |                      |                      |                   |
| - Bulk Drugs/chemicals                          | 7,458.53             | 7,176.76              | 7,135.10             | 7,458.53             | 7,135.10             | 6,278.80          |
| - Property                                      | 802.98               | 722.11                | 860.03               | 802.98               | 860.03               | 813.85            |
| - Unallocated                                   | 24,428.51            | 25,024.88             | 22,468.91            | 24,428.51            | 22,468.91            | 22,608.22         |
| Total Segment Liabilities                       | 32,690.02            | 32,923.75             | 30,464.04            | 32,690.02            | 30,464.04            | 29,700.87         |

| Particulars                                     | Consolidated         |                       |                      |                      |                      |                   |
|---|----------------------|-----------------------|----------------------|----------------------|----------------------|-------------------|
|   | Quarter ended        |                       |                      | Nine Months Ended    |                      | Year Ended        |
|   | Unaudited            | Unaudited             | Unaudited            | Unaudited            | Unaudited            | Audited           |
|   | December 31,<br>2020 | September 30,<br>2020 | December 31,<br>2019 | December 31,<br>2020 | December 31,<br>2019 | March 31,<br>2020 |
| Segment revenue                                 |                      |                       |                      |                      |                      |                   |
| - Bulk drugs/chemicals                          | 8,570.70             | 8,960.89              | 6,219.55             | 26,544.09            | 21,551.51            | 27,550.83         |
| - Property                                      | 435.22               | 452.02                | 430.21               | 1,323.59             | 1,515.45             | 1,963.05          |
| - Unallocated                                   | 66.08                | 94.11                 | 348.05               | 287.85               | 1,038.51             | 1,313.70          |
| Total   | 9,072.00             | 9,507.02              | 6,997.81             | 28,155.53            | 24,105.46            | 30,827.58         |
| Less : Inter-segment revenue                    | 4.50                 | 4.50                  | 4.61                 | 13.50                | 296.12               | 300.36            |
| Total Income                                    | 9,067.50             | 9,502.52              | 6,993.19             | 28,142.03            | 23,809.34            | 30,527.22         |
| Segment results                                 |                      |                       |                      |                      |                      |                   |
| - Bulk drugs/chemicals                          | 1,627.90             | 2,194.87              | 767.25               | 5,622.78             | 4,840.87             | 5,533.83          |
| - Property                                      | 239.06               | 251.36                | 98.82                | 712.72               | 434.98               | 563.10            |
| - Unallocated (Net)                             | (78.14)              | (67.43)               | 480.15               | (216.71)             | 170.71               | 157.41            |
| Total   | 1,788.82             | 2,378.80              | 1,346.22             | 6,118.79             | 5,446.57             | 6,254.34          |
| Less: Inter-segment results                     | 0.42                 | 0.44                  | (0.45)               | 1.28                 | (1.27)               | 1.71              |
| Total Profit before tax and before finance cost | 1,789.24             | 2,379.24              | 1,345.77             | 6,120.07             | 5,445.30             | 6,256.05          |
| Less : Finance costs                            | (392.76)             | (544.67)              | (534.81)             | (1,295.05)           | (1,514.92)           | (1,914.04)        |
| Total Profit before tax                         | 1,396.48             | 1,834.57              | 810.96               | 4,825.02             | 3,930.38             | 4,342.01          |
| Segment Assets                                  |                      |                       |                      |                      |                      |                   |
| - Bulk Drugs/chemicals                          | 49,039.82            | 45,072.08             | 38,674.58            | 49,039.82            | 38,674.58            | 40,580.16         |
| - Property                                      | 7,666.77             | 7,682.38              | 8,254.45             | 7,666.77             | 8,254.45             | 8,069.03          |
| - Unallocated                                   | 12,940.95            | 15,351.10             | 13,792.82            | 12,940.95            | 13,792.82            | 12,718.26         |
| Total Segment Assets                            | 69,647.54            | 68,105.56             | 60,721.86            | 69,647.54            | 60,721.86            | 61,367.45         |
| Segment Liabilities                             |                      |                       |                      |                      |                      |                   |
| - Bulk Drugs/chemicals                          | 9,376.52             | 8,583.72              | 7,144.27             | 9,376.52             | 7,144.27             | 7,289.02          |
| - Property                                      | 813.56               | 722.69                | 862.51               | 813.56               | 862.51               | 814.09            |
| - Unallocated                                   | 24,136.13            | 24,743.35             | 22,380.75            | 24,136.13            | 22,380.75            | 22,319.56         |
| Total Segment Liabilities                       | 34,326.21            | 34,049.76             | 30,387.53            | 34,326.21            | 30,387.53            | 30,422.67         |

W  
RKH  
AMS

- 2 The unaudited financial results included in the above statement of standalone and consolidated results includes the financial information of four subsidiaries and one associate on the basis of unaudited financial information prepared by the Management which have not been reviewed or audited by their auditors. The said interim financial information is not material to the consolidated results.
- 3 These unaudited standalone and consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The National Company Law Tribunal, Mumbai Bench, has approved the Scheme of Amalgamation between DIL Limited and Fermenta Biotech Limited and their respective shareholders, and the name of DIL Limited has been changed to Fermenta Biotech Limited. The Scheme has become effective from 26th September, 2019. The appointed date of the Scheme is 1st April, 2018. The amalgamation had been accounted as common control transaction in accordance with Appendix C of Ind AS 103 'Business Combinations'.
- 5 The earnings per share for the quarter and nine months ended 31st December, 2019 had been adjusted for bonus shares in accordance with Ind AS 33 "Earnings per Share" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued hereunder. The Board of Directors on its meeting held on 24th December, 2019 had issued bonus shares in the ratio of two fully paid up equity share of ₹ 5/- each for every one existing fully paid up equity share of ₹ 5/- each held by the members. The record date for implementation of above corporate event was fixed on 14th February, 2020.
- 6 As per the current assessment of the situation based on the internal and external information available up to the date of approval of these unaudited financial results by the Board of Directors, the Company believes that the Impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited. The eventual outcome of the impact of the global health pandemic may be different from those-estimated as on the date of approval of these unaudited standalone financial results and unaudited consolidated financial results and the Company will closely monitor any material changes to the economic environment and their impact on its business in the times to come.
- 7 The Company had given (unsecured) Inter-corporate deposits aggregating ₹ 2,130.00 Lakhs in various tranches to another entity for the development of the new product i.e. cholesterol from Fish Oil. The amount outstanding as on 31st December, 2020 is ₹ 1,407.36 Lakhs, including interest of ₹ 162.36 Lakhs. Subsequent to the end of the quarter, the other entity has further repaid an amount of ₹ 92.71 Lakhs towards the aggregate outstanding as mentioned above. The Company has started the export sales of the new product and is confident that it shall be able to recover the Inter corporate deposit amount along with interest in next 6 months. The statutory auditors have modified their review report in respect of the foregoing matter.
- 8 On 1st December, 2020, Fermenta Biotech USA, LLC, a wholly owned subsidiary of the Company, has acquired 52% of membership interest in AGD Nutrition, LLC which is in to similar line of business of the Company. The Company is in the process of determining the fair values as at the acquisition date, which is expected to be completed with in the period of 12 months as stipulated by the Ind AS 103-'Business Combinations'. Pending such determination, for the purpose of drawing the unaudited consolidated financial results of the Company for the quarter and nine months ended 31st December, 2020, the business combination has been accounted on provisional basis. The name of AGD Nutrition LLC has since been changed to Fermenta USA LLC.
- 9 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in these financial results when the Rules/Schemes thereunder are notified.
- 10 The above unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31st December, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2021. The statutory auditors of the Company have conducted a limited review of the above unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2020.

Place: Thane

11th February, 2021

AMS RKH



**Krishna Datla**  
Managing Director